PFA
FBIO icon

Pathway Financial Advisers’s Fortress Biotech FBIO Stock Holding History

Pathway Financial Advisers’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-250
Closed -$500 – 437
2024
Q1 		$500 Buy
+250
New +$498 ﹤0.01% 442

Other funds holding FBIO

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Pathway Financial Advisers's FBIO Position: Q2 2024 in Review

Pathway Financial Advisers sold out of Fortress Biotech (FBIO) in Q2 2024, closing a stake of 250 shares — an estimated $500 sold.

Pathway Financial Advisers first reported a position in FBIO in Q1 2024 and held it in 1 quarter. The position peaked at $500 in Q1 2024. 50 funds tracked by Wall St. Rank hold FBIO as of Q2 2024.

  • Pathway Financial Advisers reported no remaining Fortress Biotech position as of Q2 2024 after selling out during the quarter.
  • Pathway Financial Advisers sold 250 Fortress Biotech shares in Q2 2024, an estimated $500.
  • Pathway Financial Advisers first reported a position in Fortress Biotech in Q1 2024 and held it in 1 quarter.
  • Pathway Financial Advisers's Fortress Biotech position peaked at $500 in Q1 2024.
  • 50 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2024.

Based on Pathway Financial Advisers's 13F filing for Q2 2024, filed 20 Aug 2024.